Handelsbanken Fonder AB Has $2.64 Million Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Handelsbanken Fonder AB raised its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 31.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,667 shares of the biotechnology company’s stock after purchasing an additional 4,200 shares during the period. Handelsbanken Fonder AB’s holdings in Ascendis Pharma A/S were worth $2,638,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD raised its holdings in Ascendis Pharma A/S by 23.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after buying an additional 336,976 shares during the last quarter. Acadian Asset Management LLC grew its holdings in Ascendis Pharma A/S by 1,461.1% during the 1st quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after acquiring an additional 234,446 shares during the period. Avoro Capital Advisors LLC raised its position in shares of Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after acquiring an additional 229,995 shares in the last quarter. Perceptive Advisors LLC acquired a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at about $16,648,000. Finally, Fred Alger Management LLC boosted its position in shares of Ascendis Pharma A/S by 65.0% during the 2nd quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock valued at $41,879,000 after purchasing an additional 120,952 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on ASND shares. TD Cowen cut their price target on Ascendis Pharma A/S from $175.00 to $157.00 and set a “buy” rating on the stock in a report on Wednesday, September 4th. Jefferies Financial Group raised their price target on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a report on Tuesday, August 13th. The Goldman Sachs Group upped their price objective on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. JPMorgan Chase & Co. reduced their target price on Ascendis Pharma A/S from $174.00 to $165.00 and set an “overweight” rating for the company in a research note on Wednesday, September 4th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $190.00 target price (up from $180.00) on shares of Ascendis Pharma A/S in a research report on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $195.00.

Ascendis Pharma A/S Trading Down 2.1 %

NASDAQ ASND opened at $129.30 on Thursday. The business has a fifty day simple moving average of $135.42 and a 200 day simple moving average of $136.11. Ascendis Pharma A/S has a 12 month low of $85.29 and a 12 month high of $161.00. The firm has a market capitalization of $7.53 billion, a P/E ratio of -13.45 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.51). Ascendis Pharma A/S had a negative net margin of 154.18% and a negative return on equity of 16,574.15%. The firm had revenue of $38.75 million during the quarter, compared to analysts’ expectations of $94.74 million. As a group, sell-side analysts predict that Ascendis Pharma A/S will post -7.15 EPS for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.